

Application No. 10/089,009

Preliminary Amendment

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

RECEIVED
CENTRAL FAX CENTER
JUN 15 2007

1. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and ~~HuT-102~~ YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

2. (Canceled)

3. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and ~~HuT-102~~ YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.

4. (Canceled)

5. (Original) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 1, wherein said interleukin-2 associated polypeptide associates with the interleukin-2R α subunit.

6-8. (Canceled)

9. (Currently Amended) A method for purifying an interleukin-2 receptor associated polypeptide, wherein said method comprises:

- (a) providing cells expressing an interleukin-2 receptor and an interleukin-2 receptor associated polypeptide,
- (b) solubilizing the cells to produce a cell extract,
- (c) contacting said cell extract with an anti-interleukin-2 receptor

Application No. 10/089,009

Preliminary Amendment

associated polypeptide antibody, wherein said antibody forms a complex with said interleukin-2 receptor associated polypeptide expressed by said cells,

- (d) eluting said interleukin-2 receptor associated polypeptide from the anti-interleukin-2 receptor associated polypeptide antibody complex, and
- (e) isolating said eluted interleukin-2 receptor associated polypeptide.

10. (Canceled)

11. (Previously Presented) The method of Claim 9, wherein said anti-interleukin-2 receptor associated polypeptide antibody is present on an immunoaffinity column.

12. (Currently Amended) The method of Claim 11, wherein said interleukin-2 receptor associated ~~protein~~ polypeptide bound to said anti-interleukin-2 receptor associated polypeptide antibody is eluted from said column.

13. (Previously Presented) The method of Claim 9, wherein said cells expressing said interleukin-2 receptor and said interleukin-2 receptor associated polypeptide are selected from the group consisting of cell lines expressing interleukin-2R α and cell lines expressing interleukin-2R β subunits.

14. (Original) The interleukin-2 receptor associated polypeptide of Claim 13, wherein said interleukin-2 receptor expressing cells are Kit 225 cells.

15. (Original) A composition comprising an interleukin-2 receptor associated polypeptide purified by the method of Claim 9.

16-22. (Canceled)

23. (Previously Presented) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 3, wherein said interleukin-2 associated polypeptide associates with the interleukin-2 R α subunit.

24-25 (Canceled)

26. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma

Application No. 10/089,009

Preliminary Amendment

PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by Kit-225 cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

27. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by HaT 102 YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

28. (Previously Presented) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by Kit-225 cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.

29. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated polypeptide is capable of forming a complex with the monoclonal antibody produced by the hybridoma PTA-82, wherein said interleukin-2 receptor associated polypeptide is expressed by HaT 102 YT cells and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.